| Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer H Jacob, L Stanisavljevic, KE Storli, KE Hestetun, O Dahl, MP Myklebust Oncotarget 8 (50), 87837, 2017 | 54 | 2017 |
| A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer H Jacob, L Stanisavljevic, KE Storli, KE Hestetun, O Dahl, MP Myklebust Scientific Reports 8 (1), 6157, 2018 | 36 | 2018 |
| An MRI-based radiomic prognostic index predicts poor outcome and specific genetic alterations in endometrial cancer H Jacob, JA Dybvik, S Ytre-Hauge, KE Fasmer, EA Hoivik, J Trovik, ... Journal of clinical medicine 10 (3), 538, 2021 | 18 | 2021 |
| Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population‐based series and a randomized phase III study on adjuvant chemotherapy K Boye, H Jacob, KAM Frikstad, JM Nesland, GM Mælandsmo, O Dahl, ... Cancer medicine 5 (8), 1840-1849, 2016 | 17 | 2016 |
| Blood metabolites associate with prognosis in endometrial cancer E Strand, IL Tangen, KE Fasmer, H Jacob, MK Halle, EA Hoivik, ... Metabolites 9 (12), 302, 2019 | 16 | 2019 |
| β-catenin and plakoglobin as prognostic markers in anal cancer. MP Myklebust, H Jacob, JE Dale, O Dahl Journal of Clinical Oncology 33 (15_suppl), e14503-e14503, 2015 | 1 | 2015 |
| INNKALLING MØTE I PROGRAMUTVALG FOR FORSKERUTDANNING M Enger, H Jacob Mars 6, 2022 | | 2022 |
| Microrna signature as a potential biomarker for predicting survival in colon cancer H Jacob, L Stanisavljevic, KE Storli, O Dahl, MP Myklebust Cancer Research 77 (13_Supplement), 469-469, 2017 | | 2017 |
| 501: The prognostic value of β-catenin in anal cancer H Jacob, O Dahl, M Myklebust European Journal of Cancer, S121, 2014 | | 2014 |
